(Q34371189)

1 August 2017

Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? (English)

1 reference

1 August 2017

1 reference

Vasiliki Petta

1

1 reference

1 August 2017

Ioannis Gkiozos

series ordinal

2

1 reference

1 August 2017

Alex Strimpakos

series ordinal

3

1 reference

1 August 2017

Konstantinos Syrigos

series ordinal

4

1 reference

1 August 2017

14 September 2013

1 reference

Cancer Chemotherapy and Pharmacology

1 August 2017

1 reference

1 August 2017

72

1 reference

1 August 2017

935-952

1 reference

1 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2223-9

1 August 2017

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

The epigenome as a target for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Global histone modifications predict prognosis of resected non small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Targeting tumor angiogenesis with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

HDAC inhibitors as anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Energy metabolism in H460 lung cancer cells: effects of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Genistein and beta-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Effects of tyroservatide on histone acetylation in lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Combination of HDAC and topoisomerase inhibitors in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Advances in preclinical small molecules for the treatment of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2223-9

10.1007/S00280-013-2223-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference